Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Kevin B. Kim et al.|New England Journal of Medicine|2010Cited by 3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2007Cited by 2.3k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Karl D. Lewis et al.|The Lancet Oncology|2012Cited by 541
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patientsMark Sausen, Victor E. Velculescu, Jillian Phallen et al.|Nature Communications|2015Cited by 484
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood FlowJames Stevenson, Peter J. O’Dwyer, Mark Rosen et al.|Journal of Clinical Oncology|2003Cited by 293